Aclaris Therapeutics, Inc. Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
Aclaris Therapeutics, Inc. (ACRS) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-25.
Discontinued › Expense Statement › Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2020-02-25
- Aclaris Therapeutics, Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2019 was $0.00.
- Aclaris Therapeutics, Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- Aclaris Therapeutics, Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2017 was $3.00K.
- Aclaris Therapeutics, Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2016 was $0.00.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 36 month |
|---|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-02-25 | |
| 2018-12-31 | $0.00 10-K · filed 2020-02-25 | |
| 2017-12-31 | $3.00K 10-K · filed 2020-02-25 | |
| 2016-12-31 | $0.00 10-K · filed 2019-03-18 | $0.00 10-K · filed 2017-03-15 |
| 2015-12-31 | $0.00 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |